HM11260C

DRUG8 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

Diabetes MellitusHealthyObesityType 2 Diabetes

Phase 1

A Study of HM11260C in Healthy Male Subject

CompletedNCT01093729

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2010-02-28End: 2010-10-31Updated: 2014-02-07

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Hanmi Pharmaceutical Company LimitedDiabetes Mellitus

Start: 2013-12-31End: 2014-12-31Target: 44Updated: 2014-02-11

Phase 2

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

CompletedNCT01452451

Hanmi Pharmaceutical Company LimitedDiabetes Mellitus

Start: 2011-12-31Updated: 2016-08-09

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

CompletedNCT02057172

Hanmi Pharmaceutical Company LimitedType 2 Diabetes

Start: 2014-01-31End: 2014-12-31Updated: 2016-08-09

Effect of LAPS-Exendin on Body Weight in Obese Population

CompletedNCT02075281

Hanmi Pharmaceutical Company LimitedObesity

Start: 2014-02-28End: 2015-02-28Updated: 2016-08-09

Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

CompletedNCT02081118

Hanmi Pharmaceutical Company LimitedType 2 Diabetes

Start: 2014-02-28End: 2015-04-30Updated: 2016-08-09

Phase 3

A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

CompletedNCT06174779

Hanmi Pharmaceutical Company LimitedObesity

Start: 2024-01-03End: 2026-03-13Updated: 2026-07-07

A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

RecruitingNCT07379333

Hanmi Pharmaceutical Company LimitedType 2 Diabetes

Start: 2026-04-13End: 2028-01-01Target: 118Updated: 2026-05-13

Related Papers

Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

BMJ Open Diabetes Research & Care2022-01-0112 citations

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study

BMJ Open Diabetes Research & Care2021-06-0114 citations

Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study

Diabetes Obesity and Metabolism2020-03-0438 citations

1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

Diabetes2019-06-01

1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

Diabetes2019-06-01

1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

Diabetes2019-06-01

53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

Diabetes2019-06-01